Esperion Therapeutics Inc. has announced the appointment of Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors as an independent director. With this addition, Esperion's Board now includes eight members. Thompson brings over two decades of experience in biopharmaceutical leadership, enhancing the company's strategic direction in cardiovascular and cardiometabolic drug development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.